ONC Company Profile and Key Details

NASDAQ : ONC

BeOne Medicines

$318.07

-5.8-1.79%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

BeOne Medicines Ltd. (ONC) stock declined over -1.79%, trading at $318.07 on NASDAQ, down from the previous close of $323.87. The stock opened at $318.85, fluctuating between $315.70 and $320.57 in the recent session.

Stock Snapshot

323.87

Prev. Close

33.99B

Market Cap

315.7

Day Low

129.3

P/E Ratio

2.46

EPS (TTM)

N/A

Cash Flow per Share

318.85

Open

106.86M

Number of Shares

320.57

Day High

62.82%

Free Float in %

N/A

Book Value

158K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 20, 2026	318.85	320.57	315.70	318.07	159.38K
Apr 17, 2026	322.33	328.39	322.30	323.87	207.22K
Apr 16, 2026	322.05	323.71	318.62	320.70	204.99K
Apr 14, 2026	305.88	315.75	305.88	310.00	287.19K
Apr 13, 2026	309.38	311.20	302.53	305.64	304.17K
Apr 10, 2026	314.88	315.77	309.22	309.66	134.41K
Apr 09, 2026	311.53	317.47	310.66	313.42	142.25K
Apr 08, 2026	311.59	314.90	309.00	312.19	237.51K
Apr 07, 2026	301.22	304.91	299.29	303.82	194.46K
Apr 06, 2026	311.30	312.40	301.34	302.49	202.02K
Apr 02, 2026	307.42	315.97	306.33	310.79	133.47K
Apr 01, 2026	303.92	312.56	303.92	308.44	343.24K
Mar 31, 2026	284.70	297.80	283.48	296.97	233.04K
Mar 30, 2026	283.81	286.59	281.13	284.08	150.85K
Mar 27, 2026	286.08	289.77	280.59	283.03	233.73K
Mar 25, 2026	279.96	285.53	279.96	283.45	159.52K
Mar 24, 2026	272.64	276.98	271.47	275.69	210.61K
Mar 23, 2026	273.95	279.25	273.50	274.73	208.46K
Mar 20, 2026	282.43	285.50	274.97	275.28	226.61K
Mar 19, 2026	280.56	283.94	279.71	282.72	103.07K

Contact Details

United States

https://beonemedicines.com 345 949 4123

About Company

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusettswith operations spanning over 45 countries across six continentsthe company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The companys strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

Stock Peers

HROWM

-0.02-0.08%

Harrow Health, Inc. 11.875% Senior Notes due 2027$26.03 HROWL

0.0478+0.19%

Harrow Health, Inc. 8.625% Senior Notes due 2026$25.61 LFMDP

-0.07-0.29%

LifeMD, Inc.$23.85 CGEM

-0.54-3.59%

Cullinan Therapeutics, Inc.$14.52 WBA

0.06+0.50%

Walgreens Boots Alliance, Inc.$11.98 MSLE

-0.87-10.00%

Satellos Bioscience Inc. Common Stock$7.83 MEDS

0.33+4.55%

TRxADE HEALTH, Inc.$7.59 KYNB

0.02+0.27%

Kyntra Bio, Inc.$7.34 YI

Company Overview

BeOne Medicines Ltd. (NASDAQ:ONC) closed at $318.07 USD, losing -$5.80 (-1.79%) from the previous close of $323.87. The stock is currently mid-range between its 52-week high and low $218.31 and $385.22. With a market capitalization of about $33.99 billion, BeOne Medicines Ltd. is classified as a large-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 243.80 thousand shares, volume is running light vs its 52-week average. Headquartered in , None, BeOne Medicines Ltd. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO John V. Oyler, the company employs approximately 11,000 people and listed since February 02, 2016. BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -8.23%, SMA50 -3.88%, SMA200 4.19%). The stock’s 14-day RSI is 37.35 (weak momentum), while the ATR of 13.14 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.32% below its high and over 64.1% above its low. Average 10-day trading volume of 232.59 thousand shares is in line with the 3-month average of 239.61 thousand, indicating normal recent market interest.

Valuation Metrics

BeOne Medicines Ltd. trades at a P/E ratio of 121.52, slightly above the S&P 500 average, with a price-to-sales ratio of 6.39 and a price-to-book ratio of 8.0 trading at moderately above to book value. The P/FCF stands at 55.72, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

BeOne Medicines Ltd. generated EPS of $0.52 over the past year. Five-year average earnings growth is 17.28%. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $425.00 to $290.00. The high target offers 33.62% upside. The low target suggests -8.83% downside. The mean target is $373.55. This offers 17.44% upside. BeOne Medicines Ltd. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 51.39%. The prior quarter beat by 75.0%. Over the last six quarters, Apple has recorded several small beats. These include -45.24% in August 07, 2024.

Shareholding & Insider Activity

BeOne Medicines Ltd. has 110.03 million shares outstanding. The public float is 872.80 million shares, elevated short interest at 2.34% of float. This equals 1.77 million shares. The short ratio is 4.36 days. Institutional investors hold 39.13% of the float. Insiders own 17.24%. BAKER BROS. ADVISORS LP holds 730.64 thousand shares, Rosenberg Aaron has 0.00 shares and Ball Titus B. has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 7.30 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, BeOne Medicines has not generated any revenue.
On valuation metrics, BeOne Medicines trades at a P/E of 121.52, P/S of 6.39 and P/B of 8.00. The current ratio is 3.41 and quick ratio is 3.08. Operationally, the company’s inventory turnover is 1.10 and cash conversion cycle is 129.63 days. Debt-to-equity is 0.46, supported by a cash flow-to-debt ratio of 0.56.

Price Forecast & Outlook

Our AI price prediction model suggests that BeOne Medicines Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.96%, with price expected at $343.40 by May 04, 2026, within a range of $331.02 to $355.99 3-Month Outlook: Projected rise of 88.98%, reaching $601.10 by July 16, 2026, with a range of $584.21 to $624.25. 1-Year Outlook: Projected gain of 16.51%, with price at $370.58 by April 20, 2027, within a range of $352.89 to $388.10.

Key Takeaways

BeOne Medicines Ltd. (NASDAQ:ONC) shares are up 10.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows BeOne Medicines Ltd. trading at a premium to the broader market with a P/E of 121.52. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $366.88, suggesting 15.35% upside. Our AI forecast model points to short-term strength (7.96% over two weeks), a medium-term rise (88.98% over three months), and a longer-term gain (16.51% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current BeOne Medicines Ltd. (ONC) stock price?

BeOne Medicines Ltd. (NASDAQ: ONC) stock price is $318.07 in the last trading session. During the trading session, ONC stock reached the peak price of $320.57 while $315.70 was the lowest point it dropped to. The percentage change in ONC stock occurred in the recent session was -1.79% while the dollar amount for the price change in ONC stock was - $5.80.

ONC's industry and sector of operation?

The NASDAQ listed ONC is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector. BeOne Medicines Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ONC?

No Data

How ONC did perform over past 52-week?

ONC's closing price is 45.7% higher than its 52-week low of $218.31 where as its distance from 52-week high of $385.22 is -17.43%.

How many employees does ONC have?

Number of ONC employees currently stands at 11,000.

Link for ONC official website?

Official Website of ONC is: https://beonemedicines.com

How do I contact ONC?

ONC could be contacted at phone 345 949 4123 and can also be accessed through its website. ONC operates from , , , United States.

How many shares of ONC are traded daily?

ONC stock volume for the day was 158K shares. The average number of ONC shares traded daily for last 3 months was 243.8K.

What is the market cap of ONC currently?

The market value of ONC currently stands at $33.99B with its latest stock price at $318.07 and 106.86M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	11000
Beta	0.52
Sales or Revenue	N/A
5Y Sales Change%	5.588%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Medical - Pharmaceuticals

ONC Company Profile and Key Details

BeOne Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview